Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR C797S/T790M/L858R (#RDB15496)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, C797S, T790M and L858R, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15496 pENTER-EGFR C797S/T790M/L858R DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR C797S/T790M/L858R was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15496).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15496_A7K8p1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: rrnB T1 ter, attL1, insert 5'
Sequence file: RDB15496_A7K8a.seq check
>D04925A9_A7K8_1_rrnBT1ter_F2_C08_08_ABI24.ab1
    1 AGCCAGGTCT TCGACTGAGC CTTTCGTTTT ATTTGATGCC TGGCAGTTCC CTACTCTCGC
   61 GTTAACGCTA GCATGGATGT TTTCCCAGTC ACGACGTTGT AAAACGACGG CCAGTCTTAA
  121 GCTCGGGCCC CAAATAATGA TTTTATTTTG ACTGATAGTG ACCTGTTCGT TGCAACAAAT
  181 TGATGAGCAA TGCTTTTTTA TAATGCCAAC TTTGTACAAA AAAGCAGGCT CCGCGGCCGC
  241 CCCCTTCACC ATGCGACCCT CCGGGACGGC CGGGGCAGCG CTCCTGGCGC TGCTGGCTGC
  301 GCTCTGCCCG GCGAGTCGGG CTCTGGAGGA AAAGAAAGTT TGCCAAGGCA CGAGTAACAA
  361 GCTCACGCAG TTGGGCACTT TTGAAGATCA TTTTCTCAGC CTCCAGAGGA TGTTCAATAA
  421 CTGTGAGGTG GTCCTTGGGA ATTTGGAAAT TACCTATGTG CAGAGGAATT ATGATCTTTC
  481 CTTCTTAAAG ACCATCCAGG AGGTGGCTGG TTATGTCCTC ATTGCCCTCA ACACAGTGGA
  541 GCGAATTCCT TTGGAAAACC TGCAGATCAT CAGAGGAAAT ATGTACTACG AAAATTCCTA
  601 TGCCTTAGCA GTCTTATCTA ACTATGATGC AAATAAAACC GGACTGAAGG AGCTGCCCAT
  661 GAGAAATTTA CAGGAAATCC TGCATGGCGC CGTGCGGTTC AGCAACAACC CTGCCCTGTG
  721 CAATGTGGAG AGCATCCAGT GGCGGGACAT AGTCAGCAGT GACTTTCTCA GCAACATGTC
  781 GATGGACTTC CAGAACCACC TGGGCAGCTG CCAAAAGTGT GATCCAAGCT GTCCCAATGG
  841 GAGCTGCTGG GGTGCAGGAG AGGAGAACTG CCAGAAACTG ACCAAAATCA TCTGTGCCCA
  901 GCAGTGCTCC GGGCGCTGCC GTGGCAAGTC CCCCAGTGAC TGCTGCCACA ACCAGTGTGC
  961 TGCAGCTGCA CAGGCCCCCG GGAGAGCGAC TGCCTGGTTC TGCCGCAATT CCGAGACGAA
 1021 GCCACGTGCA AGGACACCTG CCCCCCCCAC TCATGCTCTA CAACCCCCAA CACCGTACAA
 1081 GATGGATGTG AAACCCCGAA GGGCCAAATA CCAGCCTTTT GGTTGCCACC CTGGCGGTGA
1141 AGAAGGTGTG TTCCCCCGG
//
Primer: pDONR_R (Pr0071)
Region: attL2, insert 3'
Sequence file: RDB15496_A7K8b.seq check
>D04925A9_A7K8_1_pDONR_R_B06_06_ABI24.ab1
    1 GGAGACGCAG GCACGCTATG ACCATGTAAT ACGACTCACT ATAGGGGATA TCAGCTGGAT
   61 GGCAAATAAT GATTTTATTT TGACTGATAG TGACCTGTTC GTTGCAACAA ATTGATAAGC
  121 AATGCTTTCT TATAATGCCA ACTTTGTACA AGAAAGCTGG GTCGGCGCGC CCACCCTTTC
  181 ATGCTCCAAT AAATTCACTG CTTTGTGGCG CGACCCTTAG GTATTCTGCA TTTTCAGCTG
  241 TGGAGCCCTT AAAGATGCCA TTTGGCTTGG CTTCCTTGGG AAAGAAGTCC TGCTGGTAGT
  301 CAGGGTTGTC CAGGCTAATT TGGTGGCTGC CTTTCTGGGC CCAGTGGGCA GGGCTGTCGA
  361 ATGTGCTGTT GACACAGGTG GGCTGGACAG TGTTGAGATA CTCGGGGTTG CCCACTGCAG
  421 TGCTGTGGGG GTCCTGGTAG TGTGGGTCTC TGCTGGGCGC GGGGTTCAGA GGCTGATTGT
  481 GATAGACAGG ATTCTGCACA GAGCCAGCGG GCCTTTTGGG AACGGACTGG TTTATGTATT
  541 CAGGCACTGG GAGGAAGGTG TCGTCTATGC TGTCCTCAGT CAAGGCGCCT GTGGGGTCTG
  601 AGCTGTATCG CTGCAAGAAG CTGTCTTCCT TGATGGGACA GCTTTGCAGC CCATTTCTAT
  661 CAATGCAAGC CACGGTGGAA TTGTTGCTGG TTGCACTCAG AGAGCTCAGG AGGGGAGTCC
  721 GTGACGTGGA GGGGCTGCTG AAGAAGCCCT GCTGTGGGAT GAGGTACTCG TCGGCATCCA
  781 CCACGTCGTC CATGTCTTCT TCATCCATCA GGGCACGGTA GAAGTTGGAG TCTGTAGGAC
  841 TTGGCAAATG CATTCTTTCA TCCCCCCTGA ATGACAAGGT AGCGCTGGGG GGTCTCGGGG
  901 CCATTTTGGA GAATTCGATG ATCAACTCAC GGAAACTTTG GGCGACTATC TGCGTCTATC
  961 ATCCAGCACT TGACCATGAT CATGTAGACA TCGATGGTAC ATATGGGTGG CTGAGGGAGG
 1021 CCGTTTCTCC TTTCTCCAGG ATGGAGGAGA TCTCGCTGGC AGGATTCCGG TCATATGACT
1081 GAATTCCAAA GGATCATCCA ACCTCCCCAA AACG
//
Primer: EGFR-F5 (Pr0313)
Region: insert middle region (T790M, C797S, L858R)
Sequence file: RDB15496_A7K8c.seq check
>D04925A9_A7K8_1_EGFR-F5_C06_09_ABI24.ab1
    1 GACAAATCGA TCATCGCCAC TGGGATGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC
   61 CTGGGGATCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG
  121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA
  181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT
  241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC
  301 GTCGCTATCA AGGAATTAAG AGAAGCAACA TCTCCGAAAG CCAACAAGGA AATCCTCGAT
  361 GAAGCCTACG TGATGGCCAG CGTGGACAAC CCCCACGTGT GCCGCCTGCT GGGCATCTGC
  421 CTCACCTCCA CCGTGCAGCT CATCATGCAG CTCATGCCCT TCGGCTCCCT CCTGGACTAT
  481 GTCCGGGAAC ACAAAGACAA TATTGGCTCC CAGTACCTGC TCAACTGGTG TGTGCAGATC
  541 GCAAAGGGCA TGAACTACTT GGAGGACCGT CGCTTGGTGC ACCGCGACCT GGCAGCCAGG
  601 AACGTACTGG TGAAAACACC GCAGCATGTC AAGATCACAG ATTTTGGGCG GGCCAAACTG
  661 CTGGGTGCGG AAGAGAAAGA ATACCATGCA GAAGGAGGCA AAGTGCCTAT CAAGTGGATG
  721 GCATTGGAAT CAATTTTACA CAGAATCTAT ACCCACCAGA GTGATGTCTG GAGCTACGGG
  781 GTGACCGTTT GGGAGTTGAT GACCTTTGGA TCCAAGCCAT ATGACGGAAT CCCTGCCAGC
  841 GAGATCTCCT CCATCCTGGA GAAAGGAGAA CGCCTCCCTC AGCCACCCAT ATGTACCATC
  901 GATGTCTACA TGATCATGGT CAAGTGCTGG ATGATAGACG CAGATAGTCG CCCAAAGTTC
  961 CGTGAGTTGA TCATCGAAAT TCTCCAAAAT GACCCGAGAC CCCCCAGCGC TACCCTTTGT
 1021 TCATTTCATG GGGGATGAAA GAATGCATTT GGTAGTCCCT ACAGACTCCA ACTCTAACGT
1081 GCCTGATGGA ATGGAGAAGT ACTATGGTAC GGA
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]